Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Hits New 12-Month High – What’s Next?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) hit a new 52-week high during trading on Tuesday . The stock traded as high as $43.15 and last traded at $43.15, with a volume of 100 shares traded. The stock had previously closed at $39.8701.

Wall Street Analyst Weigh In

BIOVF has been the topic of several research analyst reports. Danske lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, February 19th. BNP Paribas Exane upgraded shares of Swedish Orphan Biovitrum to an “outperform” rating in a research report on Tuesday, February 10th. Finally, Barclays restated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Swedish Orphan Biovitrum has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Up 8.2%

The company has a market capitalization of $15.36 billion, a PE ratio of 331.95 and a beta of 0.35. The firm’s 50-day simple moving average is $39.86 and its 200 day simple moving average is $36.93. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.59 and a current ratio of 0.90.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its earnings results on Thursday, February 5th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $846.23 million for the quarter, compared to analyst estimates of $879.40 million. Swedish Orphan Biovitrum had a net margin of 1.43% and a return on equity of 15.74%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.